泡泡玛特，逆市大涨！医药巨头，突传利好

Core Viewpoint - The article highlights the significant stock performance of Pop Mart, which surged over 9% due to share buybacks and positive analyst ratings from Morgan Stanley, while also noting the approval of a new drug clinical trial by Heng Rui Pharmaceutical [5][12]. Group 1: Pop Mart Stock Performance - Pop Mart experienced a notable increase of 9.07%, closing at HKD 197.20 per share, with a peak increase of 10.40% during the trading day [6][5]. - The company repurchased 1.4 million shares on January 19, spending HKD 251 million, which contributed to the stock's upward momentum [9][11]. - Morgan Stanley's report projected Pop Mart's net profit for 2025 to be RMB 12.6 billion, indicating strong financial resources for shareholder returns [11]. Group 2: Heng Rui Pharmaceutical Developments - Heng Rui Pharmaceutical received approval for the clinical trial of its drug HRS-2141, aimed at treating type 2 diabetes, marking a significant step in its drug development pipeline [13][17]. - The company has invested approximately RMB 5.4 million in the development of HRS-2141, which is currently in the early stages of clinical trials [17]. - Despite the positive news regarding the drug approval, Heng Rui's stock fell by 4.36% to HKD 73.55 per share on January 20, reflecting market volatility [18].